Check whether a name resolves to a research listing, investigational program, or approved medicine, then open the exact product and seller records for the destination country.
Start with a peptide name and destination. The result shows what the name means in our evidence database and which local records must be checked next.
Status check updated to CagriSema in South Africa. Investigational program requiring an exact SAHPRA product record.
Novo Nordisk states that CagriSema was submitted to the US FDA in December 2025 and that an FDA decision is anticipated by late 2026. That US review does not establish South African authorization or supply. SAHPRA's registered-product service is the official route for checking an exact South African product record. No compound-specific South African authorization finding is attached here, so an online offer cannot inherit the sponsor program's identity, evidence, or regulatory status.
This is an investigational program, not an approved product for sale. A seller listing cannot inherit the sponsor's clinical identity, trial evidence, or regulatory status.
A South Africa guide to checking peptide offers against SAHPRA's current public warning, registered-medicine directory, and licensed-establishment records.
This check routes each question to the right record. It is not a medical recommendation, legal opinion, local availability claim, or commercial ranking.
Each selection has a shareable URL, so you can send someone the exact peptide and destination without losing the identity or country context.
The short answer is a routing decision, not a blanket legal, medical, or availability conclusion.
No region-wide answer is supportable from a seller page or a single database. Resolve the BPC-157 identity, choose the exact destination, then check that country’s product and seller or supply records.
The Peptide Local identity record places retatrutide in the investigational clinical-program lane. A seller-labelled vial cannot inherit the sponsor’s trial material, evidence, or regulatory status.
No. The FDA reference resolves the US medicine identity. Authorization, presentation, prescription status, current market presence, and seller authority must still be confirmed in the selected country.
Keep the active ingredient, research label, clinical program, sponsor code, and approved brand attached to their proper source.
Open the national product database and the separate pharmacy, establishment, professional, seller, or supply record linked for that country.
Match the legal seller identity, product presentation, claimed category, current status, and delivery route. Do not transfer evidence between unlike products.